keyword
MENU ▼
Read by QxMD icon Read
search

therapeutic patent

keyword
https://www.readbyqxmd.com/read/29043398/oral-paracetamol-for-patent-ductus-arteriosus-rescue-closure
#1
Pramod Pharande, Hadley Watson, Kenneth Tan, Arvind Sehgal
The objective of this study was to ascertain the efficacy of oral paracetamol in closing a symptomatic patent ductus arteriosus (PDA) when used as 'rescue' option. After obtaining ethics approval, a retrospective appraisal of the data from April 2014 to July 2015 was performed. Infants who were administered oral paracetamol either after unsuccessful therapy with ibuprofen or where it was considered contraindicated were included. A previously published echocardiographic scoring schema to stratify for ductal disease severity was used...
October 17, 2017: Pediatric Cardiology
https://www.readbyqxmd.com/read/29034836/nanomedicine-for-intranasal-delivery-to-improve-brain-uptake
#2
Amit A Patel, Ravish J Patel, Shachi R Patel
Intranasal drug delivery system provide distinct advantage over conventional drug delivery system for a drug that is pharmacokenetically or biologically unstable. Major concern for treatment of central nervous system diseases are law concentration of therapeutically active molecule within brain as blood brain barrier is creating obstacle, where intranasal drug delivery provides direct transport of therapeutically active moiety into brain via olfactory or trigeminal pathway. Nasal mucosa provides distinct advantage like improved bioavailability, law dose and quick onset of action and high patient compliance, major disadvantage is residence time of drug and irreversible entrapment of drug...
October 13, 2017: Current Drug Delivery
https://www.readbyqxmd.com/read/29034101/lamotrigine-induced-sexual-dysfunction-and-non-adherence-case-analysis-with-literature-review
#3
Kenneth R Kaufman, Melissa Coluccio, Kartik Sivaraaman, Miriam Campeas
BACKGROUND: Optimal anti-epileptic drug (AED) treatment maximises therapeutic response and minimises adverse effects (AEs). Key to therapeutic AED treatment is adherence. Non-adherence is often related to severity of AEs. Frequently, patients do not spontaneously report, and clinicians do not specifically query, critical AEs that lead to non-adherence, including sexual dysfunction. Sexual dysfunction prevalence in patients with epilepsy ranges from 40 to 70%, often related to AEDs, epilepsy or mood states...
September 2017: BJPsych Open
https://www.readbyqxmd.com/read/29032765/recent-patent-advances-for-neurodegenerative-disorders-and-its-treatment
#4
Bhavna Kumar, Deepika Sharma
BACKGROUND: Neurodegenerative disorders are one of the common diseases that affect our society with tremendous medical and financial burdens. As a whole, neurodegeneration affects individuals of all ages, but becomes increasingly frequent with age, coming to affect a very large share of our elderly population which is severely affecting the patient, caregivers, and enormously increasing the financial burden of the nation. These diseases share a very complex nature, which often result from combined genetic, environment and pathogenic factors...
October 10, 2017: Recent Patents on Drug Delivery & Formulation
https://www.readbyqxmd.com/read/29031064/fragment-based-approach-to-identify-ido1-inhibitor-building-blocks
#5
Alice Coletti, Francesca Camponeschi, Elisa Albini, Francesco Antonio Greco, Vincenzo Maione, Chiara Custodi, Federica Ianni, Ursula Grohmann, Ciriana Orabona, Francesca Cantini, Antonio Macchiarulo
Indoleamine 2,3-dioxygenase 1 (IDO1) is attracting a great deal of interest as drug target in immune-oncology being highly expressed in cancer cells and participating to the tumor immune-editing process. Although several classes of IDO1 inhibitors have been reported in literature and patent applications, only few compounds have proved optimal pharmacological profile in preclinical studies to be advanced in clinical trials. Accordingly, the quest for novel structural classes of IDO1 inhibitors is still open...
October 3, 2017: European Journal of Medicinal Chemistry
https://www.readbyqxmd.com/read/29030222/vascular-changes-in-tumors-resistant-to-a-vascular-disrupting-nanoparticle-treatment
#6
Shweta Sharma, Aman P Mann, Tarmo Mölder, Venkata Ramana Kotamraju, Robert Mattrey, Tambet Teesalu, Erkki Ruoslahti
Anti-angiogenic and vascular disrupting therapies rely on the dependence of tumors on new blood vessels to sustain tumor growth. We previously reported a potent vascular disrupting agent, a theranostic nanosystem consisting of a tumor vasculature-homing peptide (CGKRK) fused to a pro-apoptotic peptide [D(KLAKLAK)2] coated on iron oxide nanoparticles. This nanosystem showed promising therapeutic efficacy in glioblastoma (GBM) and breast cancer models. However, complete control of the tumors was not achieved, and some tumors became non-responsive to the treatment...
October 10, 2017: Journal of Controlled Release: Official Journal of the Controlled Release Society
https://www.readbyqxmd.com/read/28994619/biological-evaluation-of-benzosuberones
#7
Haider Behbehani, Kamal M Dawood, Thoraya A Farghaly
Several natural products containing benzosuberone moiety are clinically reported as anti-tumor agents. Furthermore, several synthetic benzosuberones cited in this review exhibited wide range of theraputic activities such as bacteriostatic, anti-inflammatory, antidepressants and anti-tumor activities. Our recent review provides an overview of the different methods to synthesize the benzosuberones and their extensive biological activities. Areas covered: Thirty-two patents among 130 references are cited in this review that covered the recent inhibitory activities of the benzosuberone scaffolds and their broad area of biological applications up to the first quarter of 2017...
October 10, 2017: Expert Opinion on Therapeutic Patents
https://www.readbyqxmd.com/read/28990537/nanomedicine-for-the-treatment-of-tuberculosis
#8
Zabih Ullah, Md Tanwir Athar, Abdus Samad
BACKGROUND: The diseases tuberculosis, triggered by intracellular pathogens, is a major problem for the global medical professionals. Treatments for these diseases through conventional dosage form consist of long-term therapy with multiple drugs leads to several side effects and contribute to low patient compliance and drug resistance. METHODS: The pathogens are fond to be situated in the intracellular compartments of the cells, which ultimately results in additional blockades to effective treatment...
October 6, 2017: Recent Patents on Anti-infective Drug Discovery
https://www.readbyqxmd.com/read/28971778/strategies-to-tackle-radiation-resistance-by-penetrating-cancer-stem-cell-line-of-scrimmage
#9
So-Yeon Park, Ji-Young Kim, Youngsoo Jun, Jeong-Seok Nam
BACKGROUND: Radiation therapy has become a common therapy for cancer patients and largely improved therapeutic outcomes. However, recurrence after radiation therapy is still a major unsolved concern of cancer patients. The cancer stem cells (CSCs), a small sub-population with capacity of self-renewal and differentiation into diverse types of cancer cells, are considered as strong drivers of metastasis, resistance, and recurrence. OBJECTIVE: We overview the mechanisms behind the radiation resistance of CSCs, and introduce recent patents with the potential to overcome such an obstacle...
October 3, 2017: Recent Patents on Anti-cancer Drug Discovery
https://www.readbyqxmd.com/read/28955650/xeronine-structure-and-function-computational-comparative-mastery-of-its-mystery
#10
David Morakinyo Sanni, Toluwase Hezekiah Fatoki, Ayodele Oluseyi Kolawole, Afolabi Clement Akinmoladun
Morinda citrifolia (Noni) fruit has a long history of dietary use in tropical regions of the world. Pharmacological properties that have been attributed to the fruit include anti-inflammatory, anti-cancer, and antioxidant properties. Xeronine, a small alkaloid which has been patented (US4543212) is one of the bioactive compounds of Noni fruit, which is believed to be capable of modifying the molecular structure of specific inactive proteins thereby regulating proper folding to active enzymes. Despite reports of the potential of Xeronine as therapeutic agent, its presence is controversial and its structure has not been explored...
2017: In Silico Pharmacology
https://www.readbyqxmd.com/read/28949014/hysterosalpingo-foam-sonography-hyfosy-tolerability-safety-and-the-occurrence-of-pregnancy-post-procedure
#11
Keisuke Tanaka, Jackie Chua, Robert Cincotta, Emma L Ballard, Gregory Duncombe
BACKGROUND: Fallopian tube patency testing is an essential part of infertility evaluation. Hysterosalpingo-contrast sonography (HyCoSy) has been described as reliable, well tolerated and safe compared to other modalities such as laparoscopy and a dye test or hysterosalpingography. Limited availability of the previously used contrast has led to the introduction of a foam contrast agent as an alternative. AIMS: To assess the tolerability, safety and occurrence of pregnancy post-procedure of hysterosalpingo-foam sonography (HyFoSy)...
September 26, 2017: Australian & New Zealand Journal of Obstetrics & Gynaecology
https://www.readbyqxmd.com/read/28944738/an-industry-update-the-latest-developments-in-therapeutic-delivery
#12
Oliver C Steinbach
The present industry update covers the period 1-30 June 2017, with information sourced from company press releases, regulatory and patent agencies as well as scientific literature. The combination of drug and devices such as improved, safer injectables (see various market reports, companies Adamis and Baxter), patches (Microdermis) and (nano)carriers are moving increasingly from the R&D stage into clinical trials and toward the market. This addresses increased safety and effectiveness requirements, limiting physico-chemical properties of active ingredients, cost-effectiveness and patient comfort through ease of use...
October 2017: Therapeutic Delivery
https://www.readbyqxmd.com/read/28933264/from-a-better-understanding-of-the-mechanisms-of-action-of-histone-deacetylases-inhibitors-to-the-progress-of-the-treatment-of-malignant-lymphomas-and-plasma-cell-myeloma
#13
Romeo-Gabriel Mihăilă
BACKGROUND: Notable progress has been made in chemo- and immunotherapy of B-cell lymphomas, but less in the treatment of T-cell lymphomas. OBJECTIVE: Histone deacetylases inhibitors are a potentially useful therapeutic mean, as an epigenetic dysregulation is present in lymphomas, and especially in T-cell types. We aimed to study the progress made in this area. METHOD: A minireview was achieved using the articles published in PubMed in the last two years and the new patents made in this field...
September 19, 2017: Recent Patents on Anti-cancer Drug Discovery
https://www.readbyqxmd.com/read/28918096/a-comprehensive-review-on-aurora-kinase-small-molecule-inhibitors-and-clinical-trial-studies
#14
REVIEW
Ankit C Borisa, Hardik G Bhatt
Aurora kinase belongs to serine/threonine kinase family which controls cell division. Therapeutic inhibition of Aurora kinase showed great promise as probable anticancer regime because of its important role during cell division. Here, in this review, we have carried out exhaustive study of various synthetic molecules reported as Aurora kinase inhibitors and developed as lead molecule at various stages of clinical trials from its discovery in 1995 to till date. We reported details of small molecules, specifically inhibiting all 3 types of Aurora kinases, which includes extensive literature search in various database like various scientific journals, patents, scifinder and PubMed database, internet resources, books, etc...
August 24, 2017: European Journal of Medicinal Chemistry
https://www.readbyqxmd.com/read/28918056/the-therapeutic-potential-of-crispr-cas9-systems-in-oncogene-addicted-cancer-types-virally-driven-cancers-as-a-model-system
#15
REVIEW
Luqman Jubair, Nigel A J McMillan
The field of gene editing is undergoing unprecedented growth. The first ex vivo human clinical trial in China started in 2016, more than 1000 US patents have been filed, and there is exponential growth in publications. The ability to edit genes with high fidelity is promising for the development of new treatments for a range of diseases, particularly inherited conditions, infectious diseases, and cancers. For cancer, a major issue is the identification of driver mutations and oncogenes to target for therapeutic effect, and this requires the development of robust models with which to prove their efficacy...
September 15, 2017: Molecular Therapy. Nucleic Acids
https://www.readbyqxmd.com/read/28918016/therapeutic-mirna-and-sirna-moving-from-bench-to-clinic-as-next-generation-medicine
#16
REVIEW
Chiranjib Chakraborty, Ashish Ranjan Sharma, Garima Sharma, C George Priya Doss, Sang-Soo Lee
In the past few years, therapeutic microRNA (miRNA) and small interfering RNA (siRNA) are some of the most important biopharmaceuticals that are in commercial space as future medicines. This review summarizes the patents of miRNA- and siRNA-based new drugs, and also provides a snapshot about significant biopharmaceutical companies that are investing for the therapeutic development of miRNA and siRNA molecules. An insightful view about individual siRNA and miRNA drugs has been depicted with their present status, which is gaining attention in the therapeutic landscape...
September 15, 2017: Molecular Therapy. Nucleic Acids
https://www.readbyqxmd.com/read/28914193/chalcone-derivatives-anti-inflammatory-potential-and-molecular-targets-perspectives
#17
Debarshi Kar Mahapatra, Sanjay Kumar Bharti, Vivek Asati
Chalcone or (E)-1,3-diphenyl-2-propene-1-one scaffold has gained considerable scientific interest in medicinal chemistry owing to its simple chemistry, ease in synthesizing a variety of derivatives and exhibiting a broad range of promising pharmacological activities by modulating several molecular targets. A number of natural and (semi-) synthetic chalcone derivatives have demonstrated admirable anti-inflammatory activity due to their inhibitory potential against various therapeutic targets like cyclooxygenase (COX), lipooxygenase (LOX), interleukins (IL), prostaglandins (PGs), nitric oxide synthase (NOS), leukotriene D4 (LTD4), nuclear factor-κB (NF-κB), intracellular cell adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), monocyte chemoattractant protein-1 (MCP-1) and TLR4/MD-2, etc...
September 14, 2017: Current Topics in Medicinal Chemistry
https://www.readbyqxmd.com/read/28912713/meta-analysis-for-clinical-evaluation-of-xingnaojing-injection-for-the-treatment-of-cerebral-infarction
#18
REVIEW
Xiao Ma, Yu X Yang, Nian Chen, Qian Xie, Tao Wang, Xuan He, Jian Wang
Objective: Xingnaojing injection (XNJ) is derived from An-Gong-Niu-Huang pill, a well-known traditional Chinese patent medicine, which is widely used for stroke. To evaluate the therapeutic effect of XNJ on cerebral infarction, an extensive meta-analysis was used. Methods: Six major electronic databases including the Chinese Biomedical Database (CBM), Wanfang, the VIP medicine information system (VMIS) and the China National Knowledge Infrastructure (CNKI), PubMed, Embase, and the Cochrane Library were examined to retrieve randomized controlled trials designed to evaluate the clinical efficacy of XNJ in treating CI before November 26, 2016...
2017: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/28912143/the-relation-between-promotional-spending-on-drugs-and-their-therapeutic-gain-a-cohort-analysis
#19
Joel Lexchin
BACKGROUND: Whether drug promotion helps or hinders appropriate prescribing by physicians is debated. This study examines the most heavily promoted drugs and the therapeutic value of those drugs to help determine whether doctors should be using promotional material to inform themselves about drugs. METHODS: Lists were constructed of the 50 most heavily promoted drugs (amount of money spent on journal advertisements and visits by sales representatives) and the 50 top-selling drugs (by dollar value) for 2013, 2014 and 2015...
September 13, 2017: CMAJ Open
https://www.readbyqxmd.com/read/28901856/recent-patents-and-emerging-therapeutics-on-ocular-inflammation-and-allergy
#20
Vibhuti Agrahari, Zach Aulgur, Siddhant Thukral, Nikhil Dhall, Ryan Conely, Ashim K Mitra
BACKGROUND: Ocular inflammation and allergic eye diseases range from mild to severe may disturbs visual function and affects quality of life. Since these diseases require intensive therapies, the pathophysiology and treatments of these conditions are highlighted. OBJECTIVE: The ocular diseases caused by inflammation and allergy are extensively studied in this review to provide an overview of the newer compounds, novel delivery approaches, preclinical and clinical trials for treatment of the allergic conjunctivitis, dry eye syndrome, and uveitis...
September 11, 2017: Recent Patents on Inflammation & Allergy Drug Discovery
keyword
keyword
55120
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"